Pluristem CEO, Zami Aberman Answers the Tough Questions

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem CEO, Zami Aberman Answers the Tough Questions

LOS ANGELES, CA--(Marketwired - Jun 6, 2013) - Pluristem Therapeutics Inc. ( NASDAQ : PSTI ) ( TASE : PLTR ), a leading developer of placenta-based cell therapies, recently announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its United States phase II Intermittent Claudication (IC) study (IND 15038) has been placed on clinical hold due to a serious allergic reaction in a case which required hospitalization.

Out of 74 patients enrolled in Pluristem's trials to date, this is the first case of a serious allergic event. This event occurred in a patient with multiple diseases which may have influenced the severity of the event. The patient was discharged from the hospital the following day, following the resolution of all her symptoms.

The FDA will issue a letter within the next 30 days detailing a list of questions and requests for information from Pluristem. Zami Aberman, Pluristem's Chairman and CEO, took time to answer questions about the company .

Q: What do you mean by the word "serious"?

Aberman: According to the FDA a serious adverse event (SAE) in human drug trials is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening or requires inpatient hospitalization .

Q: So did the patient have anaphylactic shock?

Aberman: The patient did not go into anaphylactic shock and her vital signs were stable from the time she was first seen by medical professionals and during her short hospitalization.

Q: Does this mean that most likely you have to run an additional safety study in US?

Aberman: No, we will do the risk assessment based on the FDA's questions, investigate what happened and continue the phase II study once the FDA is satisfied with our responses.

Q: What exactly is involved with a clinical hold? Does this affect any of your other trials?

Aberman: A clinical hold means that we will not recruit additional patients into the US study until the FDA lifts the hold. This does not affect the other trials, namely our muscle injury trial or intermittent trial, both in Germany.

What are the principal goals of the IC study (I have the clinicaltrials.gov description) and what is the proposed timetable?

Aberman: The principal goals of the IC Phase 2b, dose escalation study is to evaluate the safety and efficacy of three different doses of our PLacental Expanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). We anticipate that enrollment to the study will be completed during H1/2014.

Q: Any thoughts on how the clinical hold might affect that timetable?

Aberman: We were notified by our regulator representative working with the FDA about the clinical hold in the US due to a serious allergic reaction. According the FDA guidelines, within 30 days we will receive written notification that will include all the questions and clarifications needed. We have enjoyed an excellent working relationship with the FDA for several years and have received valuable assistance on more than once occasion as we work together to make cell therapy a reality. We will work continue to fully cooperation with the FDA, as we have in the past, to resume the clinical trial. We hope that in the upcoming weeks we will clarify with the FDA all their issues in order to continue our trial in the US as planned. Hopefully there will be a minimal, if at all, influence on the trials' timetable.

Q: Given the extensive exclusion criteria and the fact that the company has not previously experienced a serious allergic event with PLX, any thoughts as to what the company will examine first in this case?

Aberman: The patient suffered from serious background diseases and was chronically oxygen dependent. Approximately 12 hours following the intramuscular treatment with our PLX cells, the patient noted a rash and experienced shortness of breath. She was treated in the hospital and released approximately 12 hours after admission following the resolution of all her symptoms. We are investigating to see if there are connections between her reaction and our treatment.

Q: Also, what is the immediate impact, if any, of the clinical hold on the company's other development activities?

Aberman: The only trial effected by the hold is the PLX-PAD phase II Intermittent Claudication (IC) study and the CLI study in the U.S. There is no impact on the PLX-PAD other clinical trials outside the US underway or planned at this time.

Q: Finally, is there any additional information/background that would help our readers understand the PLX technology, the IC study or the effect of the clinical hold?

Aberman: Pluristem's PLX cells are mesenchymal-like adherent stromal cells (ASCs) derived from full term human placentas. These cells are expanded in the company's proprietary bioreactor system that creates a three-dimensional (3D) microenvironment. This 3D technology allows for the controlled, large-scale growth of cells implementing an optimized, standardized, scaled-up and "hands-off" operation. This allows PLX cells to be mass-produced with batch-to-batch consistency in an effective and controllable process. Furthermore, Pluristem's 3D expansion technology allows for the production of specific PLX cell products for each of the Company's targeted indications.

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Media Contacts Only: M. Davila Assistant Editor BioMedReports.Com e-mail: Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 0

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 156

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 145

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 22

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Wells Fargo's Insight on Industrial Stocks Amid Elections

Updated Category News Views 231

Wells Fargo's Industrial Sector Election Guide As the US presidential election approaches, Wells Fargo has closely examined the Industrials sector, pinpointing potential winners and those stocks that may face challenges. This analysis is particularly noteworthy given the significant changes in policy that may arise depending on the election outcome. Key Areas of Focus in...

Continue Reading
Woodward Secures Airbus Supplier Role for A350 Actuation System

Updated Category News Views 318

Woodward Partners with Airbus for A350 Spoiler Actuation Woodward, a prominent player in aerospace and energy control solutions, has been selected as a key supplier for Airbus's A350 Spoiler Actuation System. This collaboration marks another significant milestone in their long-standing relationship, demonstrating Woodward’s commitment to providing top-notch technology...

Continue Reading
GreenPower Motor Company Secures Significant Loan for Growth

Updated Category News Views 327

GreenPower Motor Company Announces Successful Loan Closure GreenPower Motor Company Inc. (NASDAQ: GP) has officially completed the third tranche of its secured term loan offering, securing an impressive aggregate principal amount of U.S. $300,000. The company specializes in designing and distributing all-electric, purpose-built, zero-emission vehicles tailored for various...

Continue Reading
Carrier Global's Strategic Moves to Enhance Market Growth

Updated Category News Views 383

Understanding Carrier Global's Transformation Journey Carrier Global Corporation (NYSE: CARR) is a leading entity in the heating, ventilation, and air conditioning (HVAC) industry, known for its ongoing transformation since its spin-off in 2020. This article delves into the company’s strategic maneuvers, financial trajectory, and competitive positioning to inform...

Continue Reading
International School of Permanent Makeup Enhances Education Offerings

Updated Category News Views 252

International School of Permanent Makeup Unveils New Website The International School of Permanent Makeup (ISPMU) has officially launched its redesigned website, providing an updated platform for aspiring beauty professionals to explore advanced certification courses. This move reflects ISPMU's commitment to delivering top-quality education in the permanent makeup field....

Continue Reading